Kolon TissueGene, Inc.

Languages

  • English
  • Korean
  • English
  • About
    • Overview
    • History
    • Management Team
    • Board of Directors
    • Advisory Boards
  • Technology
    • Overview
    • TG-C
    • Publications
  • Product Pipeline
    • Overview
    • Applications
  • Clinical Trials
  • IR
    • Stock Data
    • PR
    • IR Material
    • Disclosure
    • Analyst Report
  • Partnering/Alliances
  • Contact

Analyst Report

IR

IR

  • Stock Data
  • PR
  • IR Material
  • Disclosure
  • Analyst Report
DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

Oct 13, 2017

Company: 미래에셋대우
Analyst: 김태희

Kolon TissueGene, Aiming for DMOAD Designation

Kolon TissueGene, Aiming for DMOAD Designation

Oct 13, 2017

Company: Mirae Asset
Analyst: Taehee Kim

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

Oct 12, 2017

Company: 미래에셋대우
Analyst: 김태희

Kolon TissueGene, Invossa Could Be Osteoarthritis Game-Changer

Kolon TissueGene, Invossa Could Be Osteoarthritis Game-Changer

Sep 26, 2017

Company: Samsung Securities
Analyst: Brian Lee

  • « Previous
  • 1
  • 2
© 2025 Kolon TissueGene, Inc. All Rights Reserved.

This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.

Privacy Policy Disclaimer Sitemap Ethical Management